echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Treatment of anal cancer precursor lesions can reduce cancer risk in HIV-infected people

    Treatment of anal cancer precursor lesions can reduce cancer risk in HIV-infected people

    • Last Update: 2021-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In a randomized clinical trial with 4446 participants (called the Anal Cancer/HSIL Prognostic Study (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), the chance of anal cancer progression Significantly reduced
    .

    This trial is the first to show such findings, and it has been tested in 21 clinical locations across the United States
    .


    Because of the importance of these findings to public health, the results of the research are being prepared for peer review and are being shared


    This study is a summary of decades of research on the history, prevention and treatment of anal cancer and its precursors
    .


    Joel Palefsky, MD, professor of medicine and lead researcher at the University of California, San Francisco, said that it also provides important information for the development of standard care guidelines for people at high risk of anal cancer, including screening and treatment of anal HSIL


    Palefsky said: "ANCHOR's data shows for the first time that even in high-risk groups, anal cancer can be prevented, such as HIV-infected people, who often have HSIL, which is difficult to treat
    .


    " "Although this study was carried out by HIV carriers.


    In 1991, Palefsky established the world's first clinic dedicated to the prevention of anal cancer in UCSF
    .


    Now known as the University of California San Francisco Anal Tumor Clinic Research and Education Center, it is currently located at the University of California San Francisco Medical Cancer Center in Mount Zion, San Francisco


    In this study, HIV-infected people aged 35 years and older with precursor lesions were randomly divided into two groups: those who received treatment for the lesion or those who did not receive treatment and actively monitored the lesion
    .

    In most cases, treatment involves a technique called hyfrecation performed in the doctor's office, in which an electric current is directed at the HSIL area to remove it
    .


    Participants were reassessed every 3 to 6 months and compared the incidence of anal cancer between the two groups


    Among HIV-infected people, the incidence of anal cancer is very high, similar to cervical cancer: both have a strong correlation with human papillomavirus, and high-grade squamous intraepithelial lesions of the cervix will occur before this
    .

    The Cervical Cancer Prevention Program detects and treats cervical HSIL that is standard care and highly effective in reducing the risk of developing cervical cancer
    .


    The researchers pointed out that the main reason for considering HSIL treatment is to reduce the risk of anal cancer




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.